Serum BCM-IMx Levels in 376 Patients with Non-Malignant Diseases

Abstract

Get full access to this article

View all access options for this article.

References

Daver

, Lennartz

, Bellia

M.F.

, Dalifard

, Lemieux

, Page

. Comparison of a new marker, BCM-EIA, to CA15.3 and MCA for detection and monitoring of breast cancer patients. Tumor Biology 1990; 11: 84.

Allende

MaT

, Vizoso

, Fueyo

, Roiz

, Lennartz

, Ruibal

. Serum BCM levels in patients with non tumoral pathologies: a volume of 25 U/ml can be used as threshold for tumoral activity. Int J Biol Markers 1990; 5: 50–1.

Allende

MaT

, Vizoso

, Roiz

, Fueyo

, Lennartz

, Ruibal

. High BCM seric levels in patients having non breast tumors. First results. Bull Cancer (Paris) 1990; 77: 1031–2.

Blankenstein

M.A.

. Analytical and clinical experience with the IMx-BCM. Satellite Symposium. BCM-breast cancer mucin-new tumor marker in breast cancer. III International Symposium on Biology and Clinical Usefulness of Tumor Markers. Madrid, September 7th.

Molina

. BCM in benign and malignant breast pathology. Satellite Symposium. BCM-breast cancer mucin-new tumor marker in breast cancer. III International Symposium on Biology and Clinical Usefulness of Tumor Markers. Madrid, September 7th.

Daver

. BCM in primary breast cancer patients. Satellite Symposium. BCM-breast cancer mucin-new tumor marker in breast cancer. III International Symposium on Biology and Clinical Usefulness of Tumor Markers. Madrid, September 7th.